Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials
- PMID: 26974879
- DOI: 10.1164/rccm.201601-0024OC
Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials
Abstract
Rationale: Optimization of β-lactam antibiotic dosing for critically ill patients is an intervention that may improve outcomes in severe sepsis.
Objectives: In this individual patient data meta-analysis of critically ill patients with severe sepsis, we aimed to compare clinical outcomes of those treated with continuous versus intermittent infusion of β-lactam antibiotics.
Methods: We identified relevant randomized controlled trials comparing continuous versus intermittent infusion of β-lactam antibiotics in critically ill patients with severe sepsis. We assessed the quality of the studies according to four criteria. We combined individual patient data from studies and assessed data integrity for common baseline demographics and study endpoints, including hospital mortality censored at 30 days and clinical cure. We then determined the pooled estimates of effect and investigated factors associated with hospital mortality in multivariable analysis.
Measurements and main results: We identified three randomized controlled trials in which researchers recruited a total of 632 patients with severe sepsis. The two groups were well balanced in terms of age, sex, and illness severity. The rates of hospital mortality and clinical cure for the continuous versus intermittent infusion groups were 19.6% versus 26.3% (relative risk, 0.74; 95% confidence interval, 0.56-1.00; P = 0.045) and 55.4% versus 46.3% (relative risk, 1.20; 95% confidence interval, 1.03-1.40; P = 0.021), respectively. In a multivariable model, intermittent β-lactam administration, higher Acute Physiology and Chronic Health Evaluation II score, use of renal replacement therapy, and infection by nonfermenting gram-negative bacilli were significantly associated with hospital mortality. Continuous β-lactam administration was not independently associated with clinical cure.
Conclusions: Compared with intermittent dosing, administration of β-lactam antibiotics by continuous infusion in critically ill patients with severe sepsis is associated with decreased hospital mortality.
Keywords: antibiotic; meropenem; pharmacodynamics; pharmacokinetics; piperacillin-tazobactam.
Comment in
-
Pooled RCTs: In sepsis, continuous (vs intermittent) antibiotic infusion reduced hospital mortality.Ann Intern Med. 2017 Feb 21;166(4):JC19. doi: 10.7326/ACPJC-2017-166-4-019. Ann Intern Med. 2017. PMID: 28241292 No abstract available.
-
Continuous or Extended Intravenous Administration of β-Lactam Antibiotics.Am J Respir Crit Care Med. 2017 Apr 15;195(8):1077-1078. doi: 10.1164/rccm.201610-2004LE. Am J Respir Crit Care Med. 2017. PMID: 28409679 No abstract available.
Similar articles
-
A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.Am J Respir Crit Care Med. 2015 Dec 1;192(11):1298-305. doi: 10.1164/rccm.201505-0857OC. Am J Respir Crit Care Med. 2015. PMID: 26200166 Clinical Trial.
-
A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.Crit Care Resusc. 2019 Mar;21(1):63-68. Crit Care Resusc. 2019. PMID: 30857514 Clinical Trial.
-
Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.Intensive Care Med. 2016 Oct;42(10):1535-1545. doi: 10.1007/s00134-015-4188-0. Epub 2016 Jan 11. Intensive Care Med. 2016. PMID: 26754759 Clinical Trial.
-
Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis.Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):155-170. doi: 10.1007/s13318-017-0439-5. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29027128 Review.
-
Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.Swiss Med Wkly. 2016 Oct 10;146:w14368. doi: 10.4414/smw.2016.14368. eCollection 2016. Swiss Med Wkly. 2016. PMID: 27731492 Review.
Cited by
-
Dose optimization of piperacillin/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in Türkiye.Eur J Clin Microbiol Infect Dis. 2024 Nov 15. doi: 10.1007/s10096-024-04990-w. Online ahead of print. Eur J Clin Microbiol Infect Dis. 2024. PMID: 39546100
-
First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion.Front Pharmacol. 2024 Oct 30;15:1347306. doi: 10.3389/fphar.2024.1347306. eCollection 2024. Front Pharmacol. 2024. PMID: 39545060 Free PMC article.
-
Artificial Intelligence to Close the Gap between Pharmacokinetic/Pharmacodynamic Targets and Clinical Outcomes in Critically Ill Patients: A Narrative Review on Beta Lactams.Antibiotics (Basel). 2024 Sep 6;13(9):853. doi: 10.3390/antibiotics13090853. Antibiotics (Basel). 2024. PMID: 39335027 Free PMC article. Review.
-
A Retrospective Analysis of Intravenous Push versus Extended Infusion Meropenem in Critically Ill Patients.Antibiotics (Basel). 2024 Sep 2;13(9):835. doi: 10.3390/antibiotics13090835. Antibiotics (Basel). 2024. PMID: 39335009 Free PMC article.
-
Guidelines for Antibiotics Prescription in Critically Ill Patients.Indian J Crit Care Med. 2024 Aug;28(Suppl 2):S104-S216. doi: 10.5005/jp-journals-10071-24677. Epub 2024 Aug 10. Indian J Crit Care Med. 2024. PMID: 39234229 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
